Keywords
Osteonecrosis
Maxilla
Angiogenesis Inhibitors
How to Cite
Abstract
Background: Drug-associated osteonecrosis of the jaws is defined as area of the jaws exposed for more than 8 weeks in patients treated with antiresorptive drugs, in the absence of previous metastasis or radiation, by interruption of blood flow to the bone tissue. Given the lack of specific epidemiological studies at the national level, the frequency cannot be determined with certainty, making it imperative to study it. Objective: to describe the cases of drug-associated osteonecrosis of the jaws in patients attended at the Alma Mater Hospital of Antioquia in the city of Medellin between January 2019 and January 2023, as well as the etiological, epidemiological, clinical, imaging and therapeutic factors. Materials and methods: retrospective descriptive study in patients with absence of maxillary pathological conditions and older than 18 years old; 56 histories were evaluated reviewing causal factor, immunological and histopathological diagnostic aids, described clinic and treatment plan in each of the cases. Results: 56 people were identified, the average age was 63.58 +/- 5 years, 41 patients were women (73%) and 15 men (27%). The site of greatest presentation was at the mandibular level (84%). Conclusions: This study demonstrates that both antiresorptive medications and oral surgical procedures are the main factors contributing to its development. Early identification and individualized care based on clinical and imaging findings are essential. Clinical outcomes improve with interdisciplinary collaboration, which is essential for effective treatment of this disease.
References
Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, et al. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. J Clin Endocrinol Metab. 2022;107(5):1441-1460.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-1956.
Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg. 2015;53(1):13-17.
Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021;7(1):47.
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356-5362.
Chaurand-Lara J, Pacheco-Ruiz L, Trejo-Campos JL, Facio-Umaña JA, Mora-Perez J. Incidencia de osteonecrosis de los maxilares por el uso de inhibidores de osteoclastos en pacientes con metástasis óseas: estudio de cohorte retrospectivo. Cir Cir. 2019;87(4):396-401.
Del Castillo Pardo de Vera JL, García de Marcos JA, Arroyo Rodríguez S, Galdeano Arenas M, Calderón Polanco J. Osteonecrosis de los maxilares asociada al empleo de bifosfonatos. Rev Esp Cirug Oral y Maxilofac. 2007;29(5):295-308.
Teuber L, Foncea C, Rojas F, Bischhoffshausen K, Goñi I, Vargas A, et al. Prevalencia de osteonecrosis de los maxilares asociada a medicamentos en pacientes tratados con bifosfonatos intravenosos: análisis epidemiológico en Centro del Cáncer - Red de Salud UC-CHRISTUS. Rev. Otorrinolaringol. Cir. Cabeza Cuello. 2020;80(4):469-476.
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80(5):920-943.
Chehal H, Nikitakis NG, Islam MN, Goodchild JH, Mordini L, Bhattacharyya I. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature. Gen Dent. 2019;67(1):42-46.
Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein J, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27(2):383-394.
Ayala-González DA, Miranda-Villasana JE, Torres- Cruz YJ, Uribe-Campos A. Actualización de medicamentos asociados a necrosis avascular de los maxilares. Perspectiva y revisión de literatura. Rev ADM. 2020;77(4):197-202.
Chalem M, Medina A, Sarmiento AK. Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts. Arch Osteoporos. 2020;15(1):101.
León-Arcila ME, Valencia Llano CH. Osteonecrosis maxilar asociada a bifosfonatos en Cali, Colombia. Rev Estomatol. 2019;27(2):11-18.
Fernández-Grisales R, Joya-Grajales E, Valencia-Villegas C, Muñoz-Zapata S, Manrique RD. Knowledge, attitudes, and practices of dentists in Colombia regarding bisphosphonate-induced osteonecrosis of the jaws. Rev. CES Odont. 2020;33(1):14-21.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position paper on Bisphosphonate-Related Osteonecrosis of the Jaws —2009 Update. J Oral Maxillofac Surg. 2009;67(5):2–12.
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177-187.
Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):117-135.
O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10(10):CD003474.
Kitagawa Y, Ohga N, Asaka T, Sato J, Hata H, Helman J, et al. Imaging modalities for drugrelated osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw. Jpn Dent Sci Rev. 2019;55(1):65-70.
Baba A, Ojiri H, Goto TK, Ikeda K, Yamauchi H, Ogino N, et al. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agentrelated osteonecrosis of the jaws/medicationrelated osteonecrosis of the jaw (secondary publication). Jpn Dent Sci Rev. 2019;55(1):58-64.
Zhang W, Gao L, Ren W, Li S, Zheng J, Li S, et al. The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw. Front Immunol. 2021;12:606043.
Nochi T, Kiyono H. Innate immunity in the mucosal immune system. Curr Pharm Des. 2006;12(32):4203–4213.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23.
McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2018;24(4):527-536.
Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27(2):383-394.
Sacco R, Shah S, Leeson R, Moraschini V, de Almeida Barros Mourão CF, Akintola O, et al. Osteonecrosis and osteonyclitis of the jaw associated with tumour necrosis factor-alpha (TNF-a) inhibitors: a systematic review. Br J Oral Maxillofac Surg. 2020;58(1):25-33.
Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiødt M, Klinge B. The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis. Clin Oral Implants Res. 2018;29(Suppl 18):54–92.
Puche M, Campagna C, Fontana M, Jorquera E, Alonso G, Caputo G, et al. Agentes antirresortivos y antiangiogénicos y su relación con la osteonecrosis de los maxilares asociada a medicamentos. Rev Asoc Odontol Argent. 2019;107(2):72-78.
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medicationrelated osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270–2290.
Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Antiresorptive agentrelated osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35(1):6–19.
Hayashida S, Yamamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J Bone Miner Metab. 2020;38(1):126–134.
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen E, Guañabens N, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017;105:11-17.
Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015;44(5):568–585.
Yamamoto S, Maeda K, Kouchi I, Hirai Y, Taniike N, Yamashita D, et al. Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. J Oral Implantol. 2018;44(5):359–364.
Schimmel M, Srinivasan M, McKenna G, Müller F. Effect of advanced age and/or systemic medical conditions on dental implant survival: a systematic review and meta-analysis. Clin Oral Implants Res. 2018;29(16):311–30.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Médicas UIS